Wiskott–Aldrich Syndrome – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 Wiskott-Aldrich syndrome (WAS) is an immunological deficiency and reduced ability to form blood clots.

Etiology-

Wiskott-Aldrich syndrome is caused by mutations in the WAS gene and is inherited in an X-linked manner. Wiskott-Aldrich syndrome, X-linked thrombocytopenia (XLT), and X-linked neutropenia (XLN) are known as “WAS-related disorders” because these diseases are all caused by mutations in the WAS gene.

Epidemiology-

The estimated prevalence of WAS-related disorders is 3/1,000,000 males.

The competitive landscape of Wiskott–Aldrich Syndrome includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Wiskott–Aldrich Syndrome across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Wiskott–Aldrich Syndrome Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Wiskott–Aldrich Syndrome – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          OTL-103           Orchard Therapeutics    Phase 3

2          Cyclosporine     medac GmbH   Phase 2